PSMA PET/CT

DIAGNOSTIC_TEST10 trials

Sponsors

Sir Mortimer B. Davis - Jewish General Hospital, Jewish General Hospital, Norwegian University of Science and Technology, University Hospital, Brest, Peter MacCallum Cancer Centre, Australia

Conditions

CancerHigh Risk Prostate CancerIntermediate Risk Prostate CancerProstate AdenocarcinomaProstate CancerProstatic NeoplasmsToxiciteit in speekselklieren van uitwendige bestraling Salivary gland toxicity Xerostomiadry mouth (after radiotherapy) Xerostomia

Phase 2

SUV on PSMA PET/CT in Non-Prostate Tumors

TerminatedNCT03841760

Sir Mortimer B. Davis - Jewish General HospitalCancer

Start: 2019-07-25End: 2023-04-01Updated: 2023-04-12

Androgen-responsive POSLUMA-guided Intra-prostatic Boost

Not yet recruitingNCT07393867

Martin T. King, MD, PhDHigh Risk Prostate Cancer, Intermediate Risk Prostate Cancer, Prostate Cancer

Start: 2026-03-01End: 2027-12-01Target: 23Updated: 2026-02-06

Phase 3

PSMA PET Additive Value for Prostate Cancer Diagnosis in Men With Negative/Equivocal MRI

Active, not recruitingNCT05154162

Peter MacCallum Cancer Centre, AustraliaProstate Cancer

Start: 2022-03-02End: 2027-08-01Target: 660Updated: 2026-03-03

Unknown Phase

PILOT Quality check of PSMA PET for imaging salivary gland toxicity

Active, not recruitingNL-OMON42838

Antoni van Leeuwenhoek ZiekenhuisToxiciteit in speekselklieren van uitwendige bestraling Salivary gland toxicity Xerostomia

Start: 2016-08-01Target: 5Updated: 2024-02-28

Upregulation of PSMA Receptors After Androgen Deprivation Therapy on PSMA PET/CT Imaging in Prostate Cancer

CompletedNCT03938766

Jewish General HospitalProstate Cancer

Start: 2018-02-02End: 2020-02-01Updated: 2020-02-12

Determining the dose-effect relation of salivary gland irradiation and functional cell loss with PSMA PET

Active, not recruitingNL-OMON49750

Antoni van Leeuwenhoek Ziekenhuisdry mouth (after radiotherapy) Xerostomia

Start: 2017-11-21Target: 30Updated: 2024-02-28

PSMA-PET and MRI for Detection of Recurrent Prostate Cancer After Radical Treatment

CompletedNCT04298112

Norwegian University of Science and TechnologyProstatic Neoplasms

Start: 2020-05-01End: 2023-05-01Updated: 2024-11-15

Diagnostic Performance of PSMA PET/CT for Pre-operative Lymph Node Assessment in Intermediate and High-risk Non-metastasic Prostate Cancer (PREOP-PSMA ).

RecruitingNCT04745871

University Hospital, BrestProstate Cancer

Start: 2021-05-20End: 2027-05-20Target: 159Updated: 2025-09-12

Correlation Between PSA Levels and F-18 PSMA PET/CT Findings in Prostate Cancer Patient

RecruitingNCT06209853

Assiut UniversityProstatic Neoplasms

Start: 2024-01-20End: 2025-04-01Target: 59Updated: 2024-07-15

Exploration of the Value of PSMA PET/CT in Dynamic Monitoring of the Efficacy of Novel Endocrine Therapy in Patients With Metastatic Hormone Sensitive Prostate Cancer

Not yet recruitingNCT06387238

Peking University First HospitalProstate Adenocarcinoma

Start: 2024-05-01End: 2026-06-30Target: 150Updated: 2024-04-29

Related Papers

Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [<sup>68</sup>Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate Cancer.

2023-12-0620 citations

PRIMARY2: A phase III, multi-centre, randomised controlled trial investigating the additive diagnostic value of [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT in men with negative/equivocal MRI in the diagnosis of clinically significant prostate cancer.

Journal of Clinical Oncology2023-02-203 citations